References

  1. Clumeck N, Mwamba M, Kabeya K, Mafutamingi J, Vaira D, Ilunga K et al. The Lubumbashi trial, Lopinavir versus Nevirapine-based regimens in treatment-naïve patients in a Developing country. 13th European AIDS Conference. 12-15 October 2011. Belgrade. EACS.

  2. Kim A. HIV infection among internally displaced women residing in river populations along the congo river, D.R.Congo. AIDS Behav.2009; 13(5):914-20. PubMed | Google Scholar

  3. Wandeler G, Keiser O, Boule A, Mulenga L, Wood R, Prozesky H et al. Tenofovir in second line antiretroviral therapy in southern Africa, collaborative analysis of cohort studies. 13th European AIDS Conference. 12-15 October 2011. Belgrade. EACS.

  4. ONUSIDA-OMS. Rapport du programme des Nations Unies sur le VIH-SIDA, 2004. http://www.unaids.org/globalreport/documents/20101123. Accessed 13 April 2013.

  5. Ray YC, Neil A A, Andrew O. Distribution of health care expenditures for HIV infected patients. Clin Infect Dis. 2006; 42(7):1003-10. PubMed | Google Scholar

  6. Palella F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998; 338 (13): 853-60. PubMed | Google Scholar

  7. Streinbrook R. Providing antiretroviral therapy of HIV infection. N Engl J Med. 2001; 344(11): 844-6. PubMed | Google Scholar

  8. Moore R. Cost effectiveness of combinaison HIV therapy: 3 years later. Pharmacoeconomics. 2000; 17(4): 325-30. PubMed | Google Scholar

  9. Juan Ambrosioni, Thomas J, Cécile Delhumeau, Alexandra C, Bernard H et al. Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections. AIDS. 2012; 26(16): 2079-2086. PubMed | Google Scholar

  10. Yeni P, Hammer S, Carpenter C. Antiretroviral treatment for adult HIV-Infected in 2002, updated recommendations of the international AIDS society-USA Panel. JAMA. 2002; 288(2): 222-35. PubMed | Google Scholar

  11. Sempowski G, Haynes B. Immune reconstitution in patients with HIV infection. Ann Rev Med. 2002; 53: 269-284. PubMed | Google Scholar

  12. Poulin J, Viswanathan M, Harris J, Komanduri K, Wieder E, Ringuette N. Direct evidence for thymic function in adult humans. J Exp Med. 1999; 190(4): 479-485. PubMed | Google Scholar

  13. Schackman B, Freedberg K, Weinstein M. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-Infected adults. Arch Intern Med. 2002; 162(21): 2478-86. PubMed | Google Scholar

  14. Corbett EL, Steketee RW et al. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet. 2002; 359 (9324): 2177-87. PubMed | Google Scholar

  15. PNUD. Rapport mondial sur le développement humain, programme de Nations Unies pour le développement, 2009. http://www.dj.undp.org/pages/Off_Doc_Agr/HDR. Accessed 15 April 2013.

  16. Thierry Nobre, Noelle Biron. L'ABC à l'hôpital : le cas de la chirurgie infantile. Finance Contrôle Stratégie. 2002 ; 5(2) : 85-105. PubMed | Google Scholar

  17. Baker J. activity-Based Costing and Activity-Based Management for health care. 1998. NY, USA. Aspen Publishers. Google Scholar

  18. Forgione D, Vermeer T, Surysekar K. DRGs costs and quality of care, an agency theory perspective. Finance Account Man. 2005; 21 (3): 291-308. PubMed | Google Scholar

  19. Halgand N. La comptabilité hospitalière, encyclopedie de comptabilité, de contrôle de gestion et d'audit. 2000. Paris. Economica. Google Scholar

  20. Udpa S. Activity-Based Costing for hospital health care. Management Review. 1996; 21 (3): 83-96. PubMed | Google Scholar

  21. Dawson D, Gravelle H, Jacobs R, Martin S, Smith P. The effects of expanding patient choice of provider on waiting times, evidence from a policy experiment. Health Econ. 2007; 16(2): 113-128. PubMed | Google Scholar

  22. Kjerstard E. Prospective funding of general hospitals in Norway, incentives for higher production? Int J Health care Finance Econ. 2003; 3(4): 231-251. Google Scholar

  23. Velasco M, Losa J, Espinosa A, Sanz J, Gaspar G, Cervero M et al. Economic evaluation of assistance to HIV patients in Spanish hospital. European Journal of Internal Medicine. 2007; 18(5): 400-404. PubMed | Google Scholar

  24. Engel F, Kletz F, Moisdon J, Tonneau D. La demarche gestionnaire à l?hôpital, le PSMI. 2000. Paris. Seli-Arslan.

  25. Bozette S, Joyce G, Mc Caffrey D. Expenditures for the care of HIV-Infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001; 344(11): 817-23. PubMed | Google Scholar

  26. Binquet C, Chene G, Jacqmin GH, Journot V, Saves M, Lacoste D. Modeling changes in CD4-positive T-Lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections, the Aquitaine cohort 1996-1997. Am J Epidem. 2001; 153(4): 386-393. PubMed | Google Scholar

  27. Carolina G, Norma R, Vincent S, Mariola L, Natalia Z. Mechanisms involved in CD4 gains in HIV-Infected patients Switched to raltegravir. AIDS. 2012; 26(5): 000-000. PubMed | Google Scholar

  28. Corbeau P. Immune reconstitution under antiretroviral therapy, the new challenge in HIV-1 infection. Blood. 2011; 117(21): 5582-5590. PubMed | Google Scholar

  29. Barreiro P, Soriano V, Casas E, Gonzalez-LJ. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non nucleosides. AIDS. 2002; 16(2): 245-249. PubMed | Google Scholar

  30. A I E L-Sony. The cost to health service of human immunodefiency virus (HIV), coinfection among tuberculosis patients in Sudan. Health Policy. 2006; 75(3): 272-279. PubMed | Google Scholar

  31. Belkis Aracena, Juan Pablo Gutierrez, Stefano MB, Paul Gertler. Costs of AIDS care in Mexico: What are its main individual predictors? Arch of Med Research. 2005; 36(5): 560-566. Google Scholar

  32. Pedram S, Fabian Schellenberg, Chaiwat Ungsedhapand, Gilbert R K, Heiner C et al. Productivity cots and determinants of productivity in HIV-infected patients. Clinical Therapeutics. 2004; 26 (5): 791-800. PubMed | Google Scholar

  33. Summer J La croix, Gerard Russo. A cost-benefit analysis of voluntary routine HIV antibody testing for hospital patients. Social Sciences Medicine. 1996; 42 (9): 1259-1272. PubMed | Google Scholar

  34. Nashala M, Lubaba S, Mohammed M, Sayera B, Dilruba A. Profil Clinique du VIH-SIDA chez les patients infectés admis dans une unite spécialisée à Dhaka au Bangladesh. 2011 ; 29 (1) : 14-19. Google Scholar

  35. Manga N, Diop S, Ndour C, Dia M, Mendy A. Dépistage Tardif de l?infection à VIH à la clinique des maladies infectieuses de Fann à Dakar, circonstances de dépistage itinéraire thérapeutique des patients et facteurs déterminants. Médicine et Maladies Infectieuses. 2009 ; 39 (2) : 95-100. PubMed | Google Scholar

  36. Zannou D, Kindé G, Vigan G, Adè J, Atadokpèdé F. Profil Clinique et immunologique des patients infectés par le VIH dépistés à Cotonou au Benin. Médecine et Maladies Infectieuses. 2004 ; 34(5) : 225-228. PubMed | Google Scholar